This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, Y.-C. Articles by Hsiu-Hsi Chen, T. Search for Related Content PubMed PubMed Citation Articles by Lee, Y.-C. Articles by Hsiu-Hsi Chen, T. Related Collections Clinical Intervention Clinical Intervention: Health Policy

Cost-effectiveness Analysis between Primary and Secondary Preventive Strategies for Gastric Cancer

¹ Institute of Preventive Medicine and ² Division of Biostatistics, Graduate Institute of Epidemiology, College of Public Health; Departments of ³ Internal Medicine and ⁴ Emergency Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan; and ⁵ Health Bureau of Lienchiang County, Matsu, Taiwan

Requests for reprints: Tony Hsiu-Hsi Chen, Institute of Preventive Medicine and Division of Biostatistics, Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Room 521, No. 17, Hsu-Chow Road, 100 Taipei, Taiwan. Phone: 886-2-33228021; Fax: 886-2-23587707. E-mail: stony{at}episerv.cph.ntu.edu.tw

Objective: The present study is done to assess the relative cost-effectiveness, optimal initial age, and interscreening interval between primary and secondary prevention strategies for gastric cancer.

Methods: Base-case estimates, including variables of natural history, efficacy of intervention, and relevant cost, were derived from two preventive programs targeting a high-risk population. Cost-effectiveness was compared between chemoprevention with ¹³C urea breath testing followed by Helicobacter pylori (H. pylori) eradication and high-risk surveillance based on serum pepsinogen measurement and confirmed by endoscopy. The main outcome measure was cost per life-year gained with a 3% annual discount rate.

Results: The incremental cost-effectiveness ratio (ICER) for once-only chemoprevention at age 30 years versus no screening was U.S. $17,044 per life-year gained. Eradication of H. pylori at later age or with a periodic scheme yielded a less favorable result. Annual high-risk screening at age of 50 years versus no screening resulted in an ICER of U.S. $29,741 per life-year gained. The ICERs of surveillance did not substantially vary with different initial ages or interscreening intervals. Chemoprevention could be dominated by high-risk surveillance when the initial age was older than 44 years. Otherwise, chemoprevention was more cost-effective than high-risk surveillance, either at ceiling ratios of U.S. $15,762 or up to U.S. $50,000. The relative cost-effectiveness was most sensitive to the infection rate of H. pylori and proportion of early gastric cancer in all detectable cases.

Conclusions: Early H. pylori eradication once in lifetime seems more cost-effective than surveillance strategy. However, the choice is still subject to the risk of infection, detectability of early gastric cancer, and timing of intervention. (Cancer Epidemiol Biomarkers Prev 2007;16(5):875–85)

This article has been cited by other articles:

				Y.-C. Lee, J.-M. Liou, C.-Y. Wu, and J.-T. Lin Review: Eradication of Helicobacter pylori to prevent gastroduodenal diseases: Hitting more than one bird with the same stone Therapeutic Advances in Gastroenterology, September 1, 2008; 1(2): 111 - 120. [Abstract] [PDF]

				M. J. Blaser Understanding Microbe-Induced Cancers Cancer Prevention Research, June 1, 2008; 1(1): 15 - 20. [Abstract] [Full Text] [PDF]

				S. Ramsey Gut Check: Can Cost-Effectiveness Analysis Help Eliminate Gastric Cancer in Asia? Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 873 - 874. [Full Text] [PDF]